Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Derralynn A HughesKathleen NichollsGere Sunder-PlassmannAna JovanovicUlla Feldt-RasmussenRaphael SchiffmannRoberto GiuglianiVipul JainChris ViereckJeffrey P CastelliNina SkubanJay A BarthDaniel G BichetPublished in: American journal of medical genetics. Part A (2019)